The role of HIF-1α in chemo-/radioresistant tumors

OncoTargets and Therapy

Volumn 11, Issue , 2018, Pages 3003-3011

  Xia, Yu ^a   Jiang, Lixia ^a   Zhong, Tianyu ^a  

^a GANNAN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Chemo radioresistance; HIF 1

Indexed keywords

BORTEZOMIB; CISPLATIN; ETOPOSIDE; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; SILVER NANOPARTICLE;

APOPTOSIS; AUTOPHAGY; CANCER INHIBITION; CELL METABOLISM; DNA REPAIR; DRUG EFFECT; DRUG RESISTANCE; HUMAN; MUTATION; NONHUMAN; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

EID: 85047733024     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S158206     Document Type: Review

References (74)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, vJemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
2. Cao W, Gu Y, Meineck M, Xu H. The combination of chemotherapy and radiotherapy towards more efficient drug delivery. Chem Asian J. 2014;9(1):48–57.
3. Prasad NR, Muthusamy G, Shanmugam M, Ambudkar SV. South Asian medicinal compounds as modulators of resistance to chemotherapy and radiotherapy. Cancers (Basel). 2016;8(3):E32.
4. Rueff J, Rodrigues AS. Cancer drug resistance. A brief overview from a genetic viewpoint. Methods Mol Biol. 2016;1395:1–18.
5. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005;111:127–148.
6. Kartal-Yandim M, Adan-Gokbulut A, Baran Y. Molecular mechanisms of drug resistance and its reversal in cancer. Crit Rev Biotechnol. 2016; 36(4):716–726.
7. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53(1):615–627.
8. Verduzco D, Lloyd M, Xu L, et al. Intermittent hypoxia selects for genotypes and phenotypes that increase survival, invasion, and therapy resistance. PLoS One. 2015;10(3):e0120958.
9. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83–92.
10. Liang Y, Zheng T, Song R, et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology. 2013;57(5):1847–1857.
11. Wang G, Wang JJ, Fu XL, Guang R, To ST. Advances in the targeting of HIF-1α and future therapeutic strategies for glioblastoma multiforme (review). Oncol Rep. 2017;37(2):657–670.
12. Ding Z, Yang L, Xie X, et al. Expression and significance of hypoxia-inducible factor-1 alpha and MDR1/P-glycoprotein in human colon carcinoma tissue and cells. J Cancer Res Clin Oncol. 2010;136(11): 1697–1707.
13. Wu D, Potluri N, Lu J, Kim Y, Rastinejad F. Structural integration in hypoxia-inducible factors. Nature. 2015;524(7565):303–308.
14. Lixia J, Shaohua S, Qiaofa S, Feng L, Sijun L. Expression and correlation of hypoxia inducible factor HIF-1α and HIF-2α in cervical carcinoma. J Pract Med. 2012;28:1942–1943.
15. Dong ZZ, Yao M, Wang L, Wu W, Gu X, Yao DF. Hypoxia-inducible factor-1alpha: molecular-targeted therapy for hepatocellular carcinoma. Mini Rev Med Chem. 2013;13(9):1295–1304.
16. Greco O, Scott S. Tumor hypoxia and targeted gene therapy. Int Rev Cytol. 2007;257:181–212.
17. Li Y, Li C, Shi H, Lou L, Liu P. The association between the rs11549465 polymorphism in the hif-1α gene and cancer risk: a meta-analysis. Int J Clin Exp Med. 2015;8(2):1561–1574.
18. Jiang LX, Shi QF, Shi SH, Li F, Liu SJ. Expression of hypoxia inducible factor-2 alpha in cervical squamous cell carcinoma and their clinical significance. Lab Med. 2012;27:819–821.
19. Liu ZJ, Semenza GL, Zhang HF. Hypoxia-inducible factor 1 and breast cancer metastasis. J Zhejiang Univ Sci B. 2015;16(1):32–43.
20. Zhang W, Shi X, Peng Y, et al. HIF-1α promotes epithelial-mesenchymal transition and metastasis through direct regulation of ZEB1 in colorectal cancer. PLoS One. 2015;10(6):e0129603.
21. Chen L, Shi Y, Yuan J, et al. HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy. PLoS One. 2014;9(3):e90678.
22. Ioannou M, Paraskeva E, Baxevanidou K, et al. HIF-1α in colorectal carcinoma: review of the literature. J BUON. 2015;20(3):680–689.
23. Rezvani HR, Ali N, Nissen LJ, et al. HIF-1α in epidermis: oxygen sensing, cutaneous angiogenesis, cancer, and non-cancer disorders. J Invest Dermatol. 2011;131(9):1793–1805.
24. Zhao Q, Li Y, Tan BB, Fan LQ, Yang PG, Tian Y. HIF-1α induces multidrug resistance in gastric cancer cells by inducing MiR-27a. PLoS One. 2015;10(8):e0132746.
25. Wang R, Cheng L, Xia J, Wang Z, Wu Q, Wang Z. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells. Curr Cancer Drug Targets. 2014;14(4):407–417.
26. Gao H, Xie J, Peng J, et al. Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α. Exp Cell Res. 2015;332(2):236–246.
27. Takasaki C, Kobayashi M, Ishibashi H, Akashi T, Okubo K. Expression of hypoxia-inducible factor-1α affects tumor proliferation and antiapoptosis in surgically resected lung cancer. Mol Clin Oncol. 2016;5(2):295–300.
28. Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18(20):5585–5594.
29. Unruh A, Ressel A, Mohamed HG, et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene. 2003;22(21): 3213–3220.
30. Feng H, Wang J, Chen W, et al. Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance. J Bone Oncol. 2016;5(2):67–73.
31. Yang SF, Chang CW, Wei RJ, Shiue YL, Wang SN, Yeh YT. Involvement of DNA damage response pathways in hepatocellular carcinoma. Biomed Res Int. 2014;1:153867.
32. Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of response and resistance to DNA repair targeted therapies. Clin Cancer Res. 2016;22(23):5651–5660.
33. Fortini P, Ferretti C, Dogliotti E. The response to DNA damage during differentiation: pathways and consequences. Mutat Res. 2013; 743–744(341):160–168.
34. Li L, Zhu T, Gao YF, et al. Targeting DNA damage response in the radio(chemo)therapy of non-small cell lung cancer. Int J Mol Sci. 2016; 17(6):E839.
35. Um JH, Kang CD, Bae JH, et al. Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells. Exp Mol Med. 2004; 36(3):233–242.
36. Liu Y, Bernauer AM, Yingling CM, Belinsky SA. HIF1α regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis. 2012;33(6):1187–1192.
37. Wrann S, Kaufmann MR, Wirthner R, Stiehl DP, Wenger RH. HIF mediated and DNA damage independent histone H2AX phosphorylation in chronic hypoxia. Biol Chem. 2013;394(4):519–528.
38. Logsdon DP, Grimard M, Luo M, et al. Regulation of HIF1α under hypoxia by APE1/Ref-1 impacts CA9 expression: dual targeting in patient-derived 3D pancreatic cancer models. Mol Cancer Ther. 2016;15(11):2722–2732.
39. Rezaeian AH, Wang YH, Lin HK. DNA damage players are linked to HIF-1α/hypoxia signaling. Cell Cycle. 2017;16(8):725–726.
40. Wirthner R, Wrann S, Balamurugan K, Wenger RH, Stiehl DP. Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 alpha-deficient mouse embryonic fibroblasts. Carcinogenesis. 2008;29(12):2306–2316.
41. Shenoy N, Dronca R, Quevedo F, et al. Low hypoxia inducible factor-1α (HIF-1α) expression in testicular germ cell tumors – a major reason for enhanced chemosensitivity? Chin J Cancer Res. 2017; 29(4):374–378.
42. Jin W, Wang J, Xu S, et al. Radioprotective effect on HepG2 cells of low concentrations of cobalt chloride: induction of hypoxia-inducible factor-1 alpha and clearance of reactive oxygen species. J Radiat Res. 2012;54(2):203–209.
43. Klein O, Rohwer N, de Molina KF, et al. Application of two-dimensional gel-based mass spectrometry to functionally dissect resistance to targeted cancer therapy. Proteomics Clin Appl. 2013;7(11–12):813–824.
44. Sugrue T, Lowndes NF, Ceredig R. Hypoxia enhances the radioresistance of mouse mesenchymal stromal cells. Stem Cells. 2014;32(8): 2188–2200.
45. Tan W, Zhong Z, Wang S, et al. The typical metabolic modifiers conferring improvement in cancer resistance. Curr Med Chem. 2017;24(34): 3698–3710.
46. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891–899.
47. Liu Y, Cao Y, Zhang W, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012; 11(8):1672–1682.
48. Lu CW, Lin SC, Chien CW, et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol. 2011;179(3):1405–1414.
49. Zhou M, Zhao Y, Ding Y, et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer. 2010;9:33.
50. Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012;23(11):560–566.
51. Huang CY, Kuo WT, Huang YC, Lee TC, Yu LC. Resistance to hypoxia-induced necroptosis is conferred by glycolytic pyruvate scavenging of mitochondrial superoxide in colorectal cancer cells. Cell Death Dis. 2013;4:e622.
52. Kim J, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177–185.
53. Maiso P, Huynh D, Moschetta M, et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015;75(10):2071–2082.
54. Mazure NM, Brahimihorn MC, Pouysségur J. Hypoxic mitochondria: accomplices in resistance. Bull Cancer. 2011;98(5):40–46.
55. Zhao J, Feng D, Yang L, Shen G, Zheng F, Xu B. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors. Cancer Treat Rev. 2015;41(7):623–633.
56. Krakstad C, Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer. 2010;9(1):135.
57. Mohammad RM, Muqbil I, Lowe L, et al. Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol. 2015;35(Suppl):S78–S103.
58. Nishimoto A, Kugimiya N, Hosoyama T, Enoki T, Li TS, Hamano K. HIF-1α activation under glucose deprivation plays a central role in the acquisition of anti-apoptosis in human colon cancer cells. Int J Oncol. 2014;44(6):2077–2084.
59. Rohwer N, Dame C, Haugstetter A, et al. Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One. 2010;5(8):e12038.
60. Zhao Q, Tan BB, Li Y, Fan LQ, Yang PG, Tian Y. Enhancement of drug sensitivity by knockdown of HIF-1α in gastric carcinoma cells. Oncol Res. 2016;23:129–136.
61. Pei GT, Wu CW, Lin WW. Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism. Biochem Biophys Res Commun. 2010;391(2): 1274–1279.
62. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010;6(3):322–329.
63. Song L, Liu S, Liang Z, et al. MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1α feedback loop and the Akt–mTOR signaling pathway. Tumour Biol. 2016;37(9):12161–12168.
64. Fang Y, Tan J, Zhang Q. Signaling pathways and mechanisms of hypoxia-induced autophagy in the animal cells. Cell Biol Int. 2015; 39(8):891–898.
65. Li ZY, Yang Y, Ming M, Liu B. Mitochondrial ROS generation for regulation of autophagic pathways in cancer. Biochem Biophys Res Commun. 2011;414(1):5–8.
66. Paggetti J, Viry E, Berchem G, Moussay E, Janji B. Hypoxia-induced autophagy in tumor cells: a key target for improving cancer immunotherapy. Cancer Cell Microenviron. 2014;1:e213.
67. Sannigrahi MK, Singh V, Sharma R, Panda NK, Khullar M. Role of autophagy in head and neck cancer and therapeutic resistance. Oral Dis. 2015;21(3):283–291.
68. Lei Y, Zhang D, Yu J, Dong H, Zhang J, Yang S. Targeting autophagy in cancer stem cells as an anticancer therapy. Cancer Lett. 2017;393: 33–39.
69. Liu H, He Z, Simon HU. Targeting autophagy as a potential therapeutic approach for melanoma therapy. Semin Cancer Bio. 2013;23(5): 352–360.
70. Sun Y, Xing X, Liu Q, et al. Hypoxia-induced autophagy reduces radiosensitivity by the HIF-1α/miR-210/Bcl-2 pathway in colon cancer cells. Int J Oncol. 2015;46(2):750–756.
71. Wu HM, Jiang ZF, Ding PS, Shao LJ, Liu RY. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Sci Rep. 2015;5:12291.
72. Zou YM, Hu GY, Zhao XQ, et al. Hypoxia-induced autophagy contributes to radioresistance via c-Jun-mediated Beclin1 expression in lung cancer cells. J Huazhong Univ Sci Technolog Med Sci. 2014; 34(5):761–767.
73. Jeong JK, Gurunathan S, Kang MH, et al. Hypoxia-mediated autophagic flux inhibits silver nanoparticle-triggered apoptosis in human lung cancer cells. Sci Rep. 2016;6:21688.
74. Lv B, Hua T, Li F, et al. Hypoxia-inducible factor 1 α protects mesenchymal stem cells against oxygen-glucose deprivation-induced injury via autophagy induction and PI3K/AKT/mTOR signaling pathway. Am J Transl Res. 2017;9(5):2492–2499.